SueWallSt

#117 $NAVN IPO Turbulence What Investors Weren’t Told

Dive into the Navan $NAVN controversy as we break down a securities class action tied to IPO disclosures, rising sales and marketing costs, and post IPO stock declines. This episode is for investors, traders, and anyone following tech stocks, IPOs, and market risk. Expect deep dives, real case analysis, and insights into financial transparency, growth metrics, and investor expectations.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#116 $LAKE Growth Strategy or Cracks in the Foundation Inside Lakeland Fallout

Dive into the Lakeland Industries $LAKE controversy as we break down a securities class action tied to acquisitions, operational challenges, and missed financial guidance. This episode is for investors, traders, and anyone following industrial stocks, M and A strategies, and market risk. Expect deep dives, real case analysis, and insights into earnings misses, supply chain issues, and stock declines.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
 
 
 

#114 $CORT FDA Shock The Approval That Never Came

Dive into the Corcept Therapeutics $CORT controversy as we break down a securities class action tied to biotech approvals, FDA setbacks, and alleged misleading statements حول relacorilant. This episode is for investors, traders, and anyone following biotech stocks, clinical trials, and market volatility. Expect deep dives, case analysis, and insights into FDA risk, insider selling, and stock crashes.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#113 $ZYXI Shocking Growth or Alleged Fraud Inside Zynex Collapse

Dive into the Zynex $ZYXI controversy as we break down a massive securities class action tied to alleged overbilling, medical device supply practices, and inflated revenue growth. This episode is for investors, traders, and anyone following healthcare stocks, fraud allegations, and market risk. Expect deep dives, real case analysis, and insights into billing practices, regulatory scrutiny, and stock collapses.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#112 $ENPH Solar Shock Inventory Truth or Revenue Illusion

Unpack the Enphase Energy $ENPH controversy as we break down a securities class action tied to solar energy, inventory management, and tax credit impacts. This episode is built for investors, traders, and anyone tracking clean energy stocks, earnings volatility, and market risk. We dive into safe harbor revenue, channel inventory concerns, and shifting guidance with sharp analysis and real case insights.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#111 $SMR Nuclear Promises or Costly Reality Unpacking the NuScale Lawsuit

Dive into the NuScale Power $SMR controversy as we break down a high stakes securities class action involving nuclear energy, small modular reactors, and alleged misleading disclosures about key partner ENTRA1. This episode is for investors, traders, and anyone following energy stocks, clean energy, and stock market risk. Expect deep dives, case analysis, and sharp insights into financial reporting and investor transparency.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#110 $OST Ostin Technology Scandal The Billion Dollar Pump and Dump Collapse

Dive into the explosive Ostin Technology Group $OST case as we break down an alleged billion dollar pump and dump scheme, shareholder lawsuit, and federal charges. This episode is for retail investors, traders, and anyone interested in stock market fraud, securities litigation, and financial news. Expect deep dives, real case analysis, and engaging discussion on market manipulation and investor risk.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#109 $PYPL PayPal Branded Checkout Growth Story or Execution Breakdown

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $PYPL PayPal and its ambitious Branded Checkout growth targets. We examine Investor Day projections, twenty percent plus long term earnings goals, Venmo and buy now pay later expansion, slowing transaction payment volume growth, withdrawal of twenty twenty seven guidance, the CEO departure, and the twenty percent stock drop that followed. This deep dive is for fintech investors, growth stock traders, and anyone tracking earnings volatility, corporate governance, and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#108 $RGNX REGENXBIO Gene Therapy Breakthrough or Clinical Hold Shock

In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $RGNX REGENXBIO and its RGX 111 gene therapy for Hurler syndrome. We break down Phase One Phase Two safety statements, no drug related serious adverse events messaging, Fast Track designation, the later FDA clinical hold after a central nervous system tumor finding, and the seventeen percent stock drop that followed. This deep dive is for biotech investors, gene therapy traders, and anyone following FDA risk, clinical trial safety, and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#107 $QURE uniQure Gene Therapy Breakthrough or Regulatory Reversal

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $QURE uniQure and its AMT 130 gene therapy for Huntington disease. We examine the seventy five percent slowing claim, the Phase One Phase Two trial using an external control from ENROLL HD, the Biologics License Application timeline, the FDA reversal on study alignment, the three hundred forty five million dollar stock offering, and the forty nine percent stock drop. This deep dive is for biotech investors, healthcare traders, and anyone following gene therapy stocks, FDA approvals, clinical trial risk, and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.